Researchers developed ebastine-loaded Solusome nanovesicle oral lyophilisates designed to disintegrate quickly in the mouth and boost systemic exposure. In rats, the formulation increased ebastine oral bioavailability 3.21-fold, positioning the approach as a potential pathway to more efficient oral delivery for existing therapeutics.